Koers Inspyr Therapeutics, Inc. Other OTC
Aandelen
NSPX
US45782A4031
Biotechnologie & Medisch Onderzoek
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 241K 223K |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | 2 mln. 1,85 mln. | Nettowinst (verlies) 2022 | -1 mln. -925K | EV/omzet 2021 | - |
Nettoliquiditeiten 2021 | 197K 182K | Nettoschuld 2022 | 305K 282K | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-0,4
x | K/w-verhouding 2022 |
-0,23
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 11-10-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Scott Ogilvie
BRD | Director/Board Member | 69 | 01-02-08 |
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Claire Thomas
BRD | Director/Board Member | 68 | 12-10-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+5,33% | 111 mld. | |
+12,11% | 105 mld. | |
-12,56% | 22,34 mld. | |
-3,70% | 21,93 mld. | |
-6,03% | 18,59 mld. | |
-35,21% | 18,12 mld. | |
-10,86% | 16,96 mld. | |
+5,10% | 13,7 mld. | |
+37,57% | 12,45 mld. |